Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

Targeting HER2 is effective in 24% of ERBB2 amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the evolution of individual metastases during treatment to discover spatially resolved determinants of resistance. Circulating tumor DNA (ctDNA) a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell 2018-07, Vol.34 (1), p.148-162.e7
Main Authors: Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Sartore-Bianchi, Andrea, Mussolin, Benedetta, Cassingena, Andrea, Martino, Cosimo, Lanman, Richard B., Nagy, Rebecca J., Fairclough, Stephen, Rospo, Giuseppe, Corti, Giorgio, Bartolini, Alice, Arcella, Pamela, Montone, Monica, Lodi, Francesca, Lorenzato, Annalisa, Vanzati, Alice, Valtorta, Emanuele, Cappello, Giovanni, Bertotti, Andrea, Lonardi, Sara, Zagonel, Vittorina, Leone, Francesco, Russo, Mariangela, Balsamo, Antonella, Truini, Mauro, Di Nicolantonio, Federica, Amatu, Alessio, Bonazzina, Erica, Ghezzi, Silvia, Regge, Daniele, Vanzulli, Angelo, Trusolino, Livio, Siena, Salvatore, Marsoni, Silvia, Bardelli, Alberto
Format: Article
Language:English
Subjects:
clonal evolution
colorectal cancer
ctDNA
HER2 amplification
lapatinib
liquid biopsy
rapid autopsy
resistance
targeted therapy
trastuzumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeting HER2 is effective in 24% of ERBB2 amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the evolution of individual metastases during treatment to discover spatially resolved determinants of resistance. Circulating tumor DNA (ctDNA) analysis identified alterations associated with resistance in the majority of refractory patients. ctDNA profiles and lesion-specific radiographic reports revealed organ- or metastasis-private evolutionary patterns. When radiologic assessments documented progressive disease in target lesions, response to HER2 blockade was retained in other metastases. Genomic and functional analyses on samples and cell models from eight metastases of a patient co-recruited to a postmortem study unveiled lesion-specific evolutionary trees and pharmacologic vulnerabilities. Lesion size and contribution of distinct metastases to plasma ctDNA were correlated. [Display omitted] •ERBB2, RAS, PIK3CA mutations are associated with resistance to HER2 blockade in mCRC•A liquid biopsy test would have identified >85% primary resistance cases•Lesion size and contribution to plasma ctDNA were correlated•Patterns of lesion-specific mutations and TCR were longitudinally compared in blood Siravegna et al. identify genetic events associated with ERBB2 amplified metastatic colorectal cancers resistant to trastuzumab plus lapatinib treatment and reveal lesion-private evolutionary patterns. Analyses of metastases from a patient unveil metastasis-specific evolution and pharmacologic vulnerabilities.
ISSN:1535-6108
1878-3686
DOI:10.1016/j.ccell.2018.06.004